Trials / Withdrawn
WithdrawnNCT03417076
Absolute Bioavailability Study With Bexagliflozin
A Phase 1, Single Center, Open-label, Single Period, Non-randomized Study to Determine the Absolute Bioavailability of Bexagliflozin Tablets Following a Single Oral Dose Co-administered With an Intravenous Microtracer Dose of 14C-Bexagliflozin in Healthy Male Subjects
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Theracos · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bexagliflozin | Bexagliflozin tablets, 20 mg, and bexagliflozin by IV |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2018-09-16
- Completion
- 2018-09-16
- First posted
- 2018-01-31
- Last updated
- 2019-09-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03417076. Inclusion in this directory is not an endorsement.